GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Cyclically Adjusted FCF per Share

LSTA (Lisata Therapeutics) Cyclically Adjusted FCF per Share : $-41.04 (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Lisata Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.539. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-41.04 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 27.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 26.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 30.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Lisata Therapeutics was 37.90% per year. The lowest was 8.90% per year. And the median was 23.20% per year.

As of today (2025-04-13), Lisata Therapeutics's current stock price is $1.95. Lisata Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-41.04. Lisata Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Lisata Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Lisata Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Cyclically Adjusted FCF per Share Chart

Lisata Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -143.40 -105.68 -95.48 -69.92 -41.04

Lisata Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.92 -62.45 -55.14 -47.46 -41.04

Competitive Comparison of Lisata Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Lisata Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lisata Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Lisata Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lisata Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.539/133.1571*133.1571
=-0.539

Current CPI (Dec. 2024) = 133.1571.

Lisata Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -58.108 99.621 -77.669
201506 -30.455 100.684 -40.278
201509 -25.747 100.392 -34.150
201512 -24.840 99.792 -33.145
201603 -23.689 100.470 -31.396
201606 -16.675 101.688 -21.835
201609 -13.547 101.861 -17.709
201612 -6.238 101.863 -8.154
201703 -18.172 102.862 -23.524
201706 -0.866 103.349 -1.116
201709 -10.480 104.136 -13.401
201712 -6.319 104.011 -8.090
201803 -9.903 105.290 -12.524
201806 -9.213 106.317 -11.539
201809 -7.512 106.507 -9.392
201812 -4.630 105.998 -5.816
201903 -8.213 107.251 -10.197
201906 -6.810 108.070 -8.391
201909 -6.422 108.329 -7.894
201912 -6.046 108.420 -7.425
202003 -5.993 108.902 -7.328
202006 5.121 108.767 6.269
202009 -2.837 109.815 -3.440
202012 -4.307 109.897 -5.219
202103 -2.840 111.754 -3.384
202106 -1.166 114.631 -1.354
202109 -1.268 115.734 -1.459
202112 -1.154 117.630 -1.306
202203 -1.398 121.301 -1.535
202206 -1.255 125.017 -1.337
202209 -0.842 125.227 -0.895
202212 -0.819 125.222 -0.871
202303 -1.026 127.348 -1.073
202306 -0.522 128.729 -0.540
202309 -0.440 129.860 -0.451
202312 -0.500 129.419 -0.514
202403 -0.847 131.776 -0.856
202406 -0.636 132.554 -0.639
202409 -0.303 133.029 -0.303
202412 -0.539 133.157 -0.539

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Lisata Therapeutics  (NAS:LSTA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Lisata Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lisata Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Executives
David W. Slack director, officer: President & CBO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti director P.O. BOX 544, BUELLTON CA 93427
Steven S Myers director 4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck officer: EVP, R&D and CMO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo officer: CLO, SVP of Corp Dev 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo director, officer: Chief Executive Officer 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo officer: SVP and CFO CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo officer: See Remarks 13 FOX MEADOW RD, SCARSDALE NY 10583
Anford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117